Skip to search formSkip to main contentSkip to account menu

Canfosfamide

Known as: (2R)-L-gamma-Glutamyl-3-((2-((bis(bis(2-chloroethyl)amino)phosphinyl)oxy)ethyl)sulfonyl)-L-alanyl-2-phenylglycine 
A modified glutathione analogue and nitrogen mustard prodrug, with potential antineoplastic activity. Canfosfamide is selectively activated by… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

TER 286
canfosfamide HCl

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Transparency in interim monitoring.
TO THE EDITOR: Most phase III randomized clinical trials (RCT) in oncology are designed to change clinical practice by… 
2013
2013
Mechanism of glutathione transferase P1-1-catalyzed activation of the prodrug canfosfamide (TLK286, TELCYTA).
Canfosfamide (TLK286, TELCYTA) is a prodrug that upon activation by glutathione transferase P1-1 (GST P1-1) yields an anticancer… 
Review
2011
Review
2011
Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer
The vulnerability of some cancer cells to oxidative signals is a therapeutic target for the rational design of new anticancer… 
Review
2011
Review
2011
New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer
IntroductionOvarian cancer is a difficult to treat cancer entity with a high relapse rate. After initial surgery and chemotherapy… 
2010
2010
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
BackgroundCanfosfamide is a novel glutathione analog activated by glutathione S-transferase P1-1. This study evaluated the safety… 
2009
2009
Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer
Introduction: We aimed to evaluate the safety and efficacy of canfosfamide in combination with carboplatin and paclitaxel as… 
Review
2009
Review
2009
Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC).
5552 Background: Canfosfamide (C) is a glutathione analog prodrug activated by glutathione S-transferase P1-1. C is synergistic… 
2009
2009
Chemotherapy: Topotecan or treosulfan—that is the question
Meier and coauthors found that topotecan improved progression-free and overall survival compared with treosulfan in patients with… 
Review
2007
Review
2007
Phase 3 Study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC)
LBA5529 Background: Canfosfamide (C) is a novel glutathione analog prodrug activated by glutathione S-transferase P1–1. C has… 
2005
2005
Canfosfamide and manufacturing method and manufacturing intermediates salt thereof, pharmaceutical compositions comprising the intermediate and its use as an anti-cancer agent
Canfosfamide and manufacturing method and manufacturing intermediates salt thereof, pharmaceutical compositions comprising the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)